Stage IV Adrenocortical Carcinoma Terminated Phase 2 Trials for Cixutumumab (DB12250)

IndicationStatusPhase
DBCOND0028759 (Stage IV Adrenocortical Carcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00778817IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTreatment